SNGX
SOLIGENIX, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.35
−1.49%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +2.5%
- EBIT
- +5.3%
- EPS
- +67.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +78.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -22.5%
- EBIT
- -25.5%
- Net income
- -34.0%
- EPS
- +57.0%
- Free cash flow
- -22.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026